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Chronic lymphocytic leukemia (CLL) is characterized by the expansion of monoclonal, mature CD5 þ /CD23 þ B cells. 1 In addition, small lymphocytic lymphoma (SLL) shares the biological characteristics of CLL; however, it is distinguished from CLL based on not exceeding 5000 clonal B-lymphocytes per ml. Here we use the term CLL throughout to denote both CLL and SLL.
A role of antigen signaling in the pathogenesis of CLL has been inferred from the observation that CLL cells use a restricted repertoire of immunoglobulin heavy chain variable (IGHV) genes, which encode antigen binding domains of the B-cell receptor Accepted article preview online 14 February 2013; advance online publication, 1 March 2013 Letters to the Editor (BCR), 2 and that many CLL cases express virtually identical BCRs, so-called 'stereotyped BCRs', that could recognize shared antigens. 3 Furthermore, clinical disease progression is predicted by whether the expressed IGHV gene has undergone somatic hypermutation (M-CLL) or not (U-CLL). 1 The U-CLL subtype is more rapidly progressive and often expresses ZAP-70, a tyrosine kinase essential for T-cell receptor signaling, which has been shown to enhance BCR signaling in vitro. 4 In addition, our recent demonstration of inducible activation of the BCR and NF-kB pathways in CLL cells in the lymph node indicating that antigendependent BCR signaling continues throughout the disease course. 5 Although both CLL subtypes showed evidence of antigen signaling in vivo, the more progressive U-CLL subtype had stronger BCR activation, higher expression of MYC and increased proliferation, suggesting that BCR signaling may contribute to clinical progression. These data indicate that BCR signaling likely has a pivotal role in the pathogenesis of CLL.
Preclinical studies identified inhibition of BCR signaling as a promising strategy in B malignancies and provided a rationale for the clinical testing of such inhibitors in these diseases. 6 Fostamatinib (a prodrug of R406) was developed as a first in class oral inhibitor of SYK, an essential downstream mediator of BCR activation. In vitro, fostamatinib inhibits BCR and integrin signaling, antagonizes the protective effect of stromal cells, reduces migration to chemokines and induces a moderate degree of apoptosis. 7, 8 In the TCL1 transgenic mouse model, fostamatinib has been shown to inhibit the growth of malignant B cells without significant alteration of normal B cells. 9 In the firstphase 1/2 clinical trial investigating fostamatinib in relapsed B-cell non-Hodgkin's lymphoma and CLL, clinical efficacy was observed in a variety of histologies with the highest response rate in CLL patients (responses and patient characteristics summarized in Supplementary Table S1) . 10 More recently, additional inhibitors of SYK, as well as inhibitors of PI3Kd and BTK, have shown in vitro and in some cases clinical activity comparable to the effects described for fostamatinib. 11 Specifically, all these kinase inhibitors reduce BCR signaling and inhibit survival and migration of CLL cells in vitro and in mouse models. [12] [13] [14] However, despite the active clinical development of these agents, no studies have yet reported on treatment-induced changes in tumor biology in patients treated with fostamatinib or other kinase inhibitors targeting the BCR.
To determine whether fostamatinib inhibits BCR-dependent activation of CLL cells in vivo, we measured the expression of representative BCR, NF-kB and MYC target genes in primary tumor samples donated by the 11 CLL patients enrolled in the phase 1/2 study of fostamatinib. Gene expression in purified CLL cells (490% CD19 þ /CD5 þ cells, using CD19 þ selection; Miltenyi Biotec, Cambridge, MA, USA) pretreatment and after one cycle of fostamatinib (day 29) was compared by quantitative PCR TaqMan assays (Supplementary Table S2 ). As a quantitative measure of the pathway inhibition in each patient, we derived a gene signature score by averaging the mRNA expression level of all target genes. Across all patients, we found that the BCR signature score was significantly reduced (decreased 3-4 fold) by fostamatinib treatment (P ¼ 0.002; Figure 1a ; Supplementary Figure S1a) . Similarly, the NF-kB target and MYC signature scores were also significantly reduced by fostamatinib in all patients evaluated (P ¼ 0.004 and 0.02, respectively; Figure 1a ; Supplementary Figures S1b and c).
We next evaluated the activation state of signal transduction proteins in these pathways. A direct downstream target of SYK is BTK. We therefore evaluated the effect of fostamatinib on BTK phosphorylation by flow cytometry. Figure 1b demonstrates treatment-induced reduction of BTK phosphorylation, pBTK(Y551), in a representative sample. By comparing pretreatment samples to day 29 samples, we found that the amount of activated BTK in CLL cells was significantly reduced by fostamatinib in all patients tested (P ¼ 0.02; Figure 1b) . Consistently, we found that levels of JUNB protein, the product of a representative NF-kB target gene, was significantly reduced by fostamatinib in all patients evaluated (Po0.001; Figure 1c ). Lastly, a reduction in MYC protein expression was seen in all patients having detectable MYC protein at baseline, consistent with the observed reduction in gene expression (P ¼ 0.03; Figure 1d ). Taken together, these data demonstrate that fostamatinib effectively inhibits BCR signal transduction and activation of downstream effector pathways in the tumor cells in vivo.
Having observed a significant decrease in BCR-mediated signaling on fostamatinib, we next assessed the effect on CLL cell activation as reflected in the expression of cell-surface markers by flow cytometry. Expression of CD69 and CD86, two activation markers known to be unregulated on CLL cells activated in vivo, 5 was decreased on CLL cells on day 29 compared with baseline (P ¼ 0.03 and 0.004, respectively; Figure 2a) . We next evaluated the expression of CD38, which is not only a prognostic marker but is also upregulated on activated CLL cells in the lymph node microenvironment. 8, 31 As expected, only in a subset of patients, X30% of the CLL population expressed CD38 (Figure 2b) . Fostamatinib reduced CD38 expression in some patients but not in others, and overall, this difference was not significant (Figure 2b) . Interestingly, in the three patients with the highest percentage of CD38-positive cells, fostamatinib had no effect on CD38 expression, and all three failed to achieve a clinical response. CLL cells of these nonresponders showed bright CD38 expression with a nearly ninefold increase in mean fluorescent intensity compared with patients achieving a clinical response (P ¼ 0.002; Figure 2b ). If confirmed in larger studies, this suggests that expression of CD38 could serve as a possible biomarker for response.
Lastly, we sought to determine whether fostamatinib could disrupt CLL cell proliferation. Tumor proliferation has been correlated with clinical outcome and is likely driven by BCR signaling. 5, 12 Using the proliferation marker, Ki67, we found a substantial decrease in the proliferative fraction of CLL cells on day 29 compared with pretreatment. The percentage of CLL cells positive for Ki67 decreased in nine of the eleven patients and across the whole group was significantly decreased by fostamatinib (P ¼ 0.005, Figure 2c ). The two patients with no detectable decrease in Ki67 expression had so few Ki67 þ cells at baseline, that a possible treatment-induced reduction could not be assessed. Together, this demonstrates that fostamatinib inhibits CLL cell activation and proliferation in vivo.
Although much preclinical data on these kinase inhibitors is now available (summarized in Wiestner 11 ) herein, we present, to our knowledge, the first ex vivo analysis of tumor samples from patients treated with fostamatinib, or any of the kinase inhibitors targeting the BCR pathway. We demonstrate that patients treated in vivo with fostamatinib display inhibition of BCR and NF-kB signaling, and reduction in activation and proliferation of the tumor cell population. An additional intriguing novel finding is the correlation of CD38 bright expression to inferior response, suggesting CD38 as a possible biomarker to predict treatment response. In immature B cells, CD38 activation leads to activation of SYK and engagement of the PI3K pathway. 15 This raises the question whether CD38 activation might be able to overcome inhibition of SYK either through increased activation of the kinase or by directly activating the downstream pathways. We suggest that future trials of novel BCR inhibitors correlate clinical activity with CD38 expression to extend our initial findings.
Fostamatinib was the first kinase inhibitor demonstrating clinical activity in relapsed mature B-cell malignancies. 10 Recently, several additional inhibitors that target kinases downstream of the BCR, including the BTK inhibitor ibrutinib and the PI3Kd inhibitor GS-1101, have shown promising clinical activity in early-stage trials. 11 Fostamatinib, ibrutinib and GS-1101 induce only a moderate degree of apoptosis in vitro, [11] [12] [13] [14] suggesting that interruption of BCR signaling and possibly other survival pathways activated in the tissue microenvironments may be responsible for the observed clinical response. The ex vivo analysis of peripheral blood-derived CLL cells presented here provides an important confirmation of target inhibition of BCR signaling by fostamatinib and demonstrates inhibition of CLL cell activation and proliferation in vivo. However, given the importance of the microenvironment in CLL pathogenesis, it will be important to extend these studies to tissue samples. Given the enthusiasm and ongoing development of novel inhibitors of BCR in CLL, our results could serve as a paradigm for future pharmacodynamic evaluation of these agents, alone, and in rational, targeted therapy combinations. 
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